1. Introduction {#sec1-ijms-19-00587}
===============

Soybean agglutinin (SBA), also known as lectin, is a major anti-nutritional factor that represents 5--7% in soybean. As the structure of SBA has stable characteristics \[[@B1-ijms-19-00587]\], such anti-nutritional factor can resist the enzymatic digestion, and induce deleterious toxic or side effects, including influencing immune response (T lymphocytes activation, inflammation and destroying cancerous cells), interaction between cell-to-cell, cell migration, apoptosis, division, cell proliferation, and signal transduction \[[@B1-ijms-19-00587],[@B2-ijms-19-00587],[@B3-ijms-19-00587]\].

SBA is a non-fiber carbohydrate related protein and has a specific binding with the gastrointestinal tract \[[@B4-ijms-19-00587]\], this mainly depends on the glycosylation (including glycoproteins, glycolipid and high glycosylation mucoprotein) in the intestinal epithelium \[[@B5-ijms-19-00587]\]. The specific binding of SBA to the intestinal epithelial cells surfaces is the precondition for deleterious toxic or side effects \[[@B6-ijms-19-00587]\]. For example, weaned pigs supplemented high levels of SBA can bind to intestinal epithelial cell, then reduce the epithelial tight junction protein (occludin) expression and increase the mucosal permeability \[[@B7-ijms-19-00587]\].

Integrins are a family member of type-I transmembrane heterodimeric glycoprotein receptors for cell adhesion \[[@B8-ijms-19-00587]\]. Such transmembrane receptors regulate cell-to-cell and cell-to-extracellular matrix interactions and signals \[[@B9-ijms-19-00587],[@B10-ijms-19-00587],[@B11-ijms-19-00587]\]. At the cellular level, functions of integrins are related to mechanical links in cell adhesion, cell migration, cell signal transduction, cell proliferation and cell apoptosis \[[@B12-ijms-19-00587],[@B13-ijms-19-00587],[@B14-ijms-19-00587]\]. Integrins are glycoproteins which are important for ligand binding. The intracellular cytoplasmic domains of integrins can associate directly with many cytoskeletal proteins and intracellular signal molecules \[[@B12-ijms-19-00587],[@B14-ijms-19-00587]\].

The related researches indicated that SBA can inhibit cell proliferation and induce cell apoptosis \[[@B1-ijms-19-00587],[@B15-ijms-19-00587]\], however the mechanism has not been reported. Our former research has identified five integrin subunits (α2, α3, α6, β1 and β4) that specially expressed in porcine intestinal columnar epithelial cells (IPEC-J2), and integrins α2, α6, and β1 were involved in SBA-induced cell cycle alteration in IPEC-J2 \[[@B15-ijms-19-00587]\]. However, no study has reported whether integrins are also involved in SBA-induced cell apoptosis (SCA) in IPEC-J2. Additionally, the relationship and connection type between SBA and integrins are still unclear.

Therefore, this research aims to determine the effects of SBA on IPEC-J2 cell proliferation and cell apoptosis; to study the roles of integrins in the process of SCA; and to illustrate the interaction and connection type between SBA and integrin subunits in IPEC-J2. The current research provided a basic for the research of the SBA anti-nutritional mechanism and we suggested that integrins can be used as a new research idea to improve SBA-induced cell biological functions alterations. The current study provided an important evidence and theoretical basic for revealing the anti-nutritional mechanism of SBA by α-actinin-2 (ACTN2) with integrins.

2. Results {#sec2-ijms-19-00587}
==========

2.1. SBA Decreased IPEC-J2 Cell Proliferation Detected by 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) Assay {#sec2dot1-ijms-19-00587}
----------------------------------------------------------------------------------------------------------------------------------

MTT was performed to determine cell proliferation in IPEC-J2. The results indicated that after being treated with 0, 0.125, 0.25, 0.5, 1.0, or 2.0 mg/mL SBA for 24 h, IPEC-J2 cell proliferation was significantly lower (*p* \< 0.05, [Figure 1](#ijms-19-00587-f001){ref-type="fig"}). When the cells were treated with 2.0 mg/mL SBA, cell proliferation (%) was lower to the lowest level, when compared with other SBA treatments (*p* \< 0.05).

2.2. Morphometric Analysis by Contrast Microscopy {#sec2dot2-ijms-19-00587}
-------------------------------------------------

With the increased concentration of SBA, the morphology and the density of the cells were changed obviously as shown in [Figure 2](#ijms-19-00587-f002){ref-type="fig"}. The main morphological differences in SBA treatments were the decreased cell numbers and the ambiguous boundaries between adjacent cells, when compared with control. Therein, 2.0 mg/mL SBA had the most significant effects on the morphology of IPEC-J2.

2.3. SBA Induced IPEC-J2 Cell Apoptosis {#sec2dot3-ijms-19-00587}
---------------------------------------

The effects of SBA on IPEC-J2 cell apoptosis were analyzed by the determination of the fraction of cells positive for active caspase-3 in different SBA treatments using flow cytometry (FCM) and the determination of Bcl-2 relative mRNA expression using quantitative real-time polymerase chain reaction (qRT-PCR).

Active caspase-3 is a marker for the cells undergoing apoptosis. After incubation with different concentrations of SBA (0, 0.125, 0.25, 0.5, 1.0, and 2.0 mg/mL) for 24 h, effects of SBA on IPEC-J2 apoptosis were determined using FCM. As shown in [Figure 3](#ijms-19-00587-f003){ref-type="fig"} and [Figure S1](#app1-ijms-19-00587){ref-type="app"}, SBA with lower concentrations (0.125, 0.25 and 0.5 mg/mL SBA) did not induce cell apoptosis (*p* \< 0.05). When the concentrations reached to a certain level (1.0 and 2.0 mg/mL SBA), fraction of cells that positive for active caspase-3 in these two SBA treatment groups were significantly higher than the control (*p* \< 0.05). When the cells were treated with 2.0 mg/mL SBA, cell apoptosis (%) was increased to the highest level, compared with other SBA treatments (*p* \< 0.05). Therefore, 2.0 mg/mL of SBA was selected as the inflection point in the next experiment, as this concentration provided the highest cell apoptosis rate than the other SBA levels.

Bcl-2 (B-cell lymphoma 2) is a member of the Bcl-2 family of regulator proteins that regulate cell death (apoptosis), and is specifically considered as an important anti-apoptotic protein. Subsequently, the effects of SBA on Bcl-2 mRNA expression was determined using qRT-PCR and the results indicated that 2.0 mg/mL SBA significantly (*p* \< 0.05) lowered the mRNA expression of Bcl-2 ([Figure 4](#ijms-19-00587-f004){ref-type="fig"}).

2.4. The Integrins Were Involved in SBA-Induced IPEC-J2 Cell Apoptosis {#sec2dot4-ijms-19-00587}
----------------------------------------------------------------------

The 10 μg/mL of integrin inhibitors \[[@B15-ijms-19-00587]\], 2.0 mg/mL SBA or both concentrations were selected to determine the roles of integrin inhibitors on cell apoptosis and SCA in IPEC-J2 by FCM ([Figure 5](#ijms-19-00587-f005){ref-type="fig"}).

After stimulation with integrin inhibitors for 24 h, the apoptosis rate was significantly increased, when compared with control (*p* \< 0.05, [Figure S2](#app1-ijms-19-00587){ref-type="app"}). This indicated that integrins α2, α3, α6, β1 and β4 were important for IPEC-J2 cell apoptosis, as the functional inhibition of any integrins can lead to cell apoptosis in IPEC-J2. The apoptosis rates in integrin inhibitor treatment groups were lower than 2.0 mg/mL SBA treatment group (*p* \< 0.05).

Since SBA can induce IPEC-J2 cell apoptosis, and integrins play an indispensable role in the apoptosis of IPEC-J2, we speculated that integrins may be involved in the process of SCA. To further demonstrate the important roles of integrin in this process, the percentage of the apoptosic cells in integrin inhibitor groups and integrin inhibitor + 2.0 mg/mL SBA treatment groups were compared and analyzed ([Figure S3](#app1-ijms-19-00587){ref-type="app"}). The results showed that apoptosic cells in integrin inhibitor α2, α3, α6, β1 or β4 treatment had no significant differences when compared with their relevant integrin inhibitor + 2.0 mg/mL SBA treatment (*p* \> 0.05), but such apoptosic cells in integrin inhibitor treatments were lower than 2.0 mg/mL SBA treatment (*p* \< 0.05). These results suggested that SBA no longer caused apoptosis in addition of integrin α2, α3, α6, β1 or β4 inhibitor. Therefore, integrins were involved in SCA in IPEC-J2.

2.5. SBA Lowered the mRNA Expression of Integrins Detected by qRT-PCR {#sec2dot5-ijms-19-00587}
---------------------------------------------------------------------

To determine the relationship between SBA and integrins (α2, α3, α6, β1 and β4) mRNA expression, mRNA levels of integrins were determined after stimulation with 0 or 2.0 mg/mL SBA for 24 h using qRT-PCR. The results showed that the mRNA expression reduction was observed in α2, α3, α6, β1 and β4 (*p* \< 0.05), when compared with control (0 mg/mL SBA treatment, [Figure 6](#ijms-19-00587-f006){ref-type="fig"}). Therefore, SBA had a negative effect on integrin α2, α3, α6, β1 and β4 mRNA levels.

2.6. Identification of the Connection Type between SBA and Integrins in IPEC-J2 {#sec2dot6-ijms-19-00587}
-------------------------------------------------------------------------------

For further estimating the connection type between SBA and integrins (direct connection or indirect connection), all the SBA-binding proteins on IPEC-J2 cell membranes were separated using co-immunoprecipitation and identified with mass spectrometry (Q--E). Direct connections between SBA and integrins have been indicated, when integrin subunits were appeared in the result of SBA-binding proteins. Otherwise, they had no direct association between them.

The extracted cell membrane proteins in IPEC-J2 were shown in [Figure 7](#ijms-19-00587-f007){ref-type="fig"}. Database searches with the peptide masses resulted in positive identification for 67 differential SBA associated proteins ([Table 1](#ijms-19-00587-t001){ref-type="table"}). Integrins did not appear in the results of SBA-binding proteins. However, one integrin associated proteins: α-actinin-2 (ACTN2) was detected in the SBA-binding proteins. These results suggested that even there was no direct physical connection between integrins and SBA, ACTN2 may be one linking protein to connect SBA with integrins.

2.7. The Relationship between SBA, Integrins and ACTN2 {#sec2dot7-ijms-19-00587}
------------------------------------------------------

α-actinin does not only work as an important cytoskeletal protein to connect with integrins, but also act as a signal regular protein \[[@B16-ijms-19-00587]\]. To determine whether SBA affects the gene expression level of integrin by *ACTN2*, the relationship between SBA and *ACTN2* gene expression was firstly detected. The qRT-PCR results indicated that after being stimulated with 2.0 mg/mL SBA for 24 h, mRNA expression of *ACTN2* was lower by 68% compared with control (*p* \< 0.05, [Figure 8](#ijms-19-00587-f008){ref-type="fig"}a).

Next, corresponding siRNA sequence of *ACTN2* were selected to reveal the relationship between ACTN2 and integrin gene expression. We transfected the IPEC-J2 with three pairs of *ACTN2*-siRNA sequences or negative control (NC) siRNA for 24 h. The efficiency of *ACTN2* in vitro silencing was confirmed by qRT-PCR. The results demonstrated that the mRNA level of *ACTN2* in the siRNA3 group was significantly lower by 59% (*p* \< 0.05), compared with the control group. Such level was even lower than the mRNA expression in both siRNA1 and siRNA2 groups. While the *ACTN2* mRNA level in NC group had no significant (*p* \> 0.05) difference when compared with the control ([Figure 8](#ijms-19-00587-f008){ref-type="fig"}b). Therefore, the sequence of *ACTN2*-siRNA3 was used for the following experiment as this treatment induced the lowest mRNA expression of *ACTN2* than the other *ACTN2*-siRNA treatment.

Then, the cells were treated with control or *ACTN2*-siRNA3 for 24 h and mRNA expression of integrins were detected using qRT-PCR. The results revealed that the mRNA levels of integrin α2, α3, α6, β1 and β4 were significantly decreased in *ACTN2*-siRNA3 treatment (*p* \< 0.05, [Figure 8](#ijms-19-00587-f008){ref-type="fig"}c). Besides, the low trends of integrin gene expression were similar in SBA treatment and *ACTN2*-siRNA3 treatment and shown in [Figure 8](#ijms-19-00587-f008){ref-type="fig"}d.

These results indicated that SBA can decrease the gene expression of *ACTN2*. The decreased gene expression of *ACTN2* by siRNA technique declined mRNA levels of integrins (α2, α3, α6, β1 and β4). Such trends were similar to the decreased gene expression of integrin induced by SBA. Therefore, SBA can reduce the mRNA expression of integrins by down regulating the gene expression level of *ACTN2*.

3. Discussion {#sec3-ijms-19-00587}
=============

Mainly, we aimed to investigate the effects of SBA on cell proliferation and cell apoptosis in IPEC-J2. The digestive epithelium is a highly organized tissue, and it requires only 3--5 days to be completely replaced. The health condition of the digestive epithelial cell proliferation and apoptosis is closely related to the nutrient digestion and absorption. In the current study, the cell proliferation of IPEC-J2 was lowered by SBA, indicating the damage effects of SBA on intestinal tract health. Bakke-McKellep et al. \[[@B17-ijms-19-00587]\] found the same trend in Atlantic salmon, and this result was consistent with the research of Pan et al. \[[@B3-ijms-19-00587]\] in IPEC-J2. In addition, we found that SBA can also induce cell apoptosis by increasing the fraction of caspase-3 positive apoptotic cells and lowering the mRNA expression of Bcl-2. Caspase-3 is a frequently activated protease in mammalian cell apoptosis \[[@B18-ijms-19-00587]\]. Caspase-3 is involved in many apoptotic pathways, such as mitochondrial, death receptor pathways and endoplasmic reticulum stress pathway. Recently, Luft, et al. \[[@B19-ijms-19-00587]\] and Nagayama and Tatsuno \[[@B20-ijms-19-00587]\] judged apoptosis as by determination of the fraction of cells positive for active caspase-3. Bcl-2 is a proto-oncogene, which can inhibit apoptosis, mainly because Bcl-2 regulates a variety of cell proliferation- and apoptosis-related protein activity \[[@B21-ijms-19-00587],[@B22-ijms-19-00587]\]. Kalashnikova et al. \[[@B23-ijms-19-00587]\] indicated that nanoparticle delivery of curcumin induces cellular hypoxia and ROS-mediated apoptosis via modulation of Bcl-2 in human neuroblastoma. The dose of the SBA (2.0 mg/mL) was selected as we previously recommended \[[@B15-ijms-19-00587]\], since this concentration has a significant inhibition rate on IPEC-J2 cell proliferation. Even there was no direct evidence to prove the effect of SBA on the apoptosis of intestinal epithelial cells, the results of Pusztai et al. \[[@B24-ijms-19-00587]\] indirectly reflected the effect of SBA on the apoptosis of rat intestinal cells. Additionally, other plant lectins can also cause cell apoptosis. For example, Galectin-8 can bind to integrins, inhibit cell adhesion, and induce apoptosis \[[@B25-ijms-19-00587]\]; Lectin of *Kaempferia rotunda* rhizome increases the percentage of the apoptosic cells in Ehrlich ascites carcinoma cells \[[@B26-ijms-19-00587]\].

Integrins are crucial to cell survival and protect anchored cells against serum starvation-induced apoptosis. When integrin-mediated cell-matrix attachment is disrupted in epithelial and endothelial cells, cell apoptosis can be induced \[[@B27-ijms-19-00587]\]. In the present research, we found that integrins played an important role in IPEC-J2 apoptosis, functional inhibition of any integrin inhibitors increased the percentage of the apoptotic cells. Pan et al. \[[@B15-ijms-19-00587]\] have demonstrated that both integrin inhibitors and SBA lowered IPEC-J2 cell proliferation through the perturbation of cell cycle progression, and integrins were involved in the SBA-induced cell cycle progression alteration. Therefore, we hypothesized that integrin may be also involved in SBA induced IPEC-J2 cell apoptosis. To elucidate whether SBA affect cell apoptosis through the integrins in IPEC-J2, SBA was added to the integrin inhibitor treated cells to observe whether SBA still induced cell apoptosis in addition of integrin inhibitors. The results showed that the SBA could not induce cell apoptosis in addition of integrin inhibitors, indicating that integrins α2, α3, α6, β1 and β4 were involved in SCA in IPEC-J2. This may be closely related to the biological function of integrins in cell apoptosis. For example, integrin β4 is vital to the cell survival and prevents the cell apoptosis in primary cultured mouse neurons \[[@B28-ijms-19-00587]\]; integrin α6 is an important protein to protect the primordial germ cells from apoptosis in the mouse \[[@B29-ijms-19-00587]\].

In our research, the relationship between SBA and mRNA expression of integrins in IPEC-J2 was further identified in this research. After being stimulated by SBA, the mRNA expression levels in integrin subunits (α2, α3, α6, β1 and β4) were significantly lower than the control. Integrin subunits play a vital role in many types of biological cell proliferation and apoptosis \[[@B12-ijms-19-00587]\], and the lowered gene levels of integrins can influence cell proliferation and cell apoptosis. For example, mammary epithelial proliferation is controlled through a signaling mechanism that demanded β1-integrin subunit, since the deletion of the β1-integrin gene inhibits cell proliferation in mammary epithelial cells \[[@B30-ijms-19-00587]\]. Down-regulation of integrin α2 gene leads to decrease the capacity of osteoblast proliferation \[[@B31-ijms-19-00587]\]. The reduction of α6 in mouse breast cancer cells can also inhibit cell proliferation \[[@B32-ijms-19-00587]\]. Chung and Mercurio \[[@B33-ijms-19-00587]\] reported that the deletion of α6β1 integrin in breast carcinoma cells induces cell apoptosis and decreases the transfer ability of the cells. β4 integrin is required for hemidesmosome formation, cell adhesion and cell survival, knockdown of β4 induces apoptosis in rat epithelial cells and Schwann cells \[[@B34-ijms-19-00587]\]. Therefore, these results indicated that, SBA may inhibit IPEC-J2 proliferation and induce cell apoptosis as SBA lowered gene expression of integrin subunits.

Since SBA can significantly affect the gene expression in relation to integrins in IPEC-J2, another aim of this research was to determine the connection type between SBA and integrins, in other words, to prove by which pattern can SBA affect mRNA expression of integrins. The results showed that integrins had no direct association with SBA, which was different from Hadari et al. \[[@B25-ijms-19-00587]\], who indicated that Galectin-8, termed S-type lectins, can bind to integrin α3, α6 and β1 and finally inhibit cell adhesion and induce cell apoptosis. This conflicting data from Hadari's to our research may be ascribed to the different actions of different lectins' kinds to interact with their ligands \[[@B35-ijms-19-00587]\]. In addition, lectins have their striking biological activities depending on lectin species, animal species, developmental stage and other factors \[[@B36-ijms-19-00587]\]. Therefore, additional research is needed to study the connection type between different types of lectins and integrin family members.

For further identification whether SBA influenced integrins gene expression by an indirect way, integrin-associated proteins in SBA-binding proteins in the IPEC-J2 cell membrane were analyzed. In the present study, one integrin-associated protein was identified in SBA-binding proteins, family members of α-actinin, ACTN2. α-actinin is a major component in isolated plasma membranes in HeLa cells, mouse myeloma cells, and gerbil fibroma cells \[[@B37-ijms-19-00587]\]. The direct association between α-actinin and integrins has been reasonably well established. For example, the central rod domain of α-actinin consists of four spectrin-like repeats, which binds to the cytoplasmic tail of integrin β1 subunits \[[@B38-ijms-19-00587]\]. A high affinity binding sites on the integrin β1 cytoplasmic domain (residues F743-A753) are binding to the central repeats of α-actinin \[[@B39-ijms-19-00587]\]. In this research, SBA lowered *ACTN2* and integrin mRNA levels. The gene expression level of these five integrin subunits was decreased after *ACTN2* gene silencing by RNA interference technique. Besides, the reduced trends of integrin gene expression were similar in SBA treatment and *ACTN2*-siRNA3 treatment. The related research demonstrated that α-actinin is not only one integrin-associated protein, but also a signal regular protein \[[@B16-ijms-19-00587]\]. For example, α-actinin plays a potential role in regulating integrin αIIbβ3 activation \[[@B40-ijms-19-00587]\]. Furthermore, α-actinin is also the main link transmitting force between integrins and the cytoskeleton in mature adhesion \[[@B41-ijms-19-00587]\]. Alteration of α-actinin expression levels can also affect integrin functions and signal transduction \[[@B42-ijms-19-00587]\]. Therefore, ACTN2 may be not only one of the proteins that binds to SBA and integrin, but also can transfer the signal of SBA to integrin. In other words, SBA may reduce the mRNA expression of integrins by down regulating the gene expression level of *ACTN2*.

The gastrointestinal epithelial cells in pigs are the most similar models to the human gastrointestinal epithelial cells \[[@B43-ijms-19-00587]\]. Thus, using of SBA in high levels for human nutrition could exhibit relevant level of gastrointestinal cell apoptosis. The residual SBA (undigested amount, %) in different animals and different intestinal digesta was analyzed according to the following model: *y* = A*i* + D*j* + A*i*D*j* + e*ij* (where *y* is the measurement of residual SBA index; A*i* is the experimental results produced by different species of animals; D*j* is the experimental results produced by different intestinal segments; A*i*D*j* is the interaction between different species of animals, and different intestinal segments; e*ij* is the random error) \[[@B44-ijms-19-00587]\]. The concentration of SBA in raw soybean is ranged between 10 to 20 mg/g, depending on the soybean species \[[@B45-ijms-19-00587]\], and the residual SBA in pig jejunum was 17% \[[@B44-ijms-19-00587]\]. Thus, the high levels of soybean (like natural grazing) or soybean products contained in diets could lead to apoptotic effect on the intestinal epithelial cells, as a result of the action of SBA.

4. Materials and Methods {#sec4-ijms-19-00587}
========================

4.1. Cell Culture {#sec4dot1-ijms-19-00587}
-----------------

IPEC-J2 (Porcine intestinal columnar epithelial cell line) was cultivated by applying standard cell culture techniques at 37 °C with 5% CO~2~ in Dulbecco's Modified Eagle Media: Nutrient Mixture F-12 (DMEM/F12) medium (Gibco, Waltham, MA, USA), supplemented with 10% (*v*/*v*) fetal bovine serum (FBS, Gibco) and 1% (*v*/*v*) penicillin-streptomycin (Sigma, St. Louis, MO, USA). The cell culture medium was exchanged every 2 days.

4.2. Cell Morphological Observation {#sec4dot2-ijms-19-00587}
-----------------------------------

IPEC-J2 was seeded at 5 × 10^4^ cells/cm^2^ in 6-well plates and cultured for 80% confluence. Then the cells were cultured with 0, 0.125, 0.25, 0.5, 1.0 or 2.0 mg/mL SBA for 24 h. Cell morphology in different treatments was observed by contrast microscopy (Olympus, Tokyo, Japan).

4.3. Cell Proliferation Assays {#sec4dot3-ijms-19-00587}
------------------------------

IPEC-J2 was seeded into 96-well plates at a density of 5 × 10^3^ cells per well for 80% confluence. Then the cells were cultured for 24 h in the presence of SBA (Sigma), dissolved in DMEM/F12 medium at concentration of 0, 0.125, 0.25, 0.5, 1.0 or 2.0 mg/mL. The media were discarded and the cell proliferation was quantified by MTT assay according to the manufacturer's instructions (Sigma). The plates were read using a multiplate reader (Multiskan FC, Thermo Scientific, Waltham, MA, USA) at 570 nm wavelength.

4.4. Cell Apoptosis Assessment by Flow Cytometry {#sec4dot4-ijms-19-00587}
------------------------------------------------

Upon reaching 80% confluence, the cells were treated with 0, 0.125, 0.25, 0.5, 1.0, or 2.0 mg/mL SBA for 24 h. FITC active caspase-3 apoptosis kit (BD Pharmingen, La Jolla, CA, USA) was used to determine the cell apoptosis by FCM according to the manufacturer's instructions. In brief, the cells in different treatments were washed with cold phosphate buffer solution (PBS), then resuspend cells in BD Cytofix/Cytoperm™ solution at a concentration of 1 × 10^6^ cells/0.5 mL. After incubation for 20 min on ice, BD Cytofix/Cytoperm™ solution was discarded and the cells were washed twice with BD Perm/Wash™ buffer at room temperature. The cells were then incubated with BD Perm/Wash™ buffer plus antibody at room temperature for 30 min. Each test was washed in 1.0 mL BD Perm/Wash™ buffer, then the test was suspended in 0.5 mL BD Perm/Wash™ buffer. A minimum of 1 × 10^4^ cells were collected and analyzed using FCM. The optimal concentration of SBA was selected for the next experiment.

4.5. qRT-PCR {#sec4dot5-ijms-19-00587}
------------

IPEC-J2 was grown on glass tissue culture flasks with the density of 1 × 10^5^ cells per flask (25 cm^2^, NUNC, A/S, Roskilde, Denmark) for 80% confluence. After treatment with 0 (control) or optimal concentration of SBA for 24 h, total RNA was extracted using Trizol reagent (Takara, Shiga, Japan) according to the manufacturer's protocol. A Nanodrop 2000 spectrophotometer (Thermo Scientific) was used to determine the yield and purity of the total RNA. 1 μg of total RNA was used for cDNA synthesis which was carried out in 20 μL reaction system using cDNA synthesis kit (Takara) following manufacturer's instruction.

qRT-PCR was performed using the SYBR Premix Ex Tap II (Tli RNaseH Plus, Takara). Thermal cycling consisted of initial denaturation for 30 s at 95 °C RT stage, followed by 5 s at 95 °C, then 30 s at 60 °C for 40 cycles, then 15 s at 95 °C, 30 s at 60°C and 15 s at 95 °C. Cycle threshold (*C*~t~) values were measured and calculated by the Sequence detector software. Relative amounts of mRNA were normalized to GAPDH and calculated with the software program Microsoft Excel. The relative mRNA expression levels of different genes were calculated using the formula: 2^−ΔΔ*C*t^ \[[@B46-ijms-19-00587]\], in which ΔΔ*C*~t~ = ΔE − ΔC, and ΔE = *C*~t\ sample~ − *C*~t\ GAPDH~ and ΔC = *C*~t\ control~ − *C*~t\ GAPDH~. The primer sequences with a concentration of 10 µM for different genes and GAPDH are shown in [Table 2](#ijms-19-00587-t002){ref-type="table"}.

4.6. Integrin Functional Inhibition Test {#sec4dot6-ijms-19-00587}
----------------------------------------

According to our previous study \[[@B15-ijms-19-00587]\], 10 µg/mL of different integrin functional inhibitors (α2: MAB1950Z; α3: MAB1952P; α6: MAB1378; β1: MAB1959; or β4: MAB2058, Millipore, MA, USA) and SBA with optimal concentration were selected in integrin inhibitor test. Brifely, the cell proliferation rate in the first effective concentration of α2 treatment was 10 µg/mL; in α3, 10 µg/mL; in α6, 5 µg/mL; in β1, 5 µg/mL and in β4 was 10 µg/mL. To ensure the consistency of experimental conditions, 10 µg/mL was selected as the final optimal concentration for each subunit in the subsequent integrin inhibitor experiments. The IPEC-J2 was seeded into 6 well plates for 80% confluence and then divided into twelve groups as shown in [Table 3](#ijms-19-00587-t003){ref-type="table"}. The cell apoptosis in different groups were measured using FCM and conducted as described before (in [Section 4.4](#sec4dot4-ijms-19-00587){ref-type="sec"}).

4.7. Effects of SBA on Integrin Gene Expression by qRT-PCR {#sec4dot7-ijms-19-00587}
----------------------------------------------------------

IPEC-J2 was grown on glass tissue culture flasks with the density of 1 × 10^5^ cells per flask (25 cm^2^, NUNC, Denmark) for 80% confluence. The relative mRNA expression levels of integrins were calculated using the formula: 2^−ΔΔ*C*t^ \[[@B46-ijms-19-00587]\]. The primer sequences with a concentration of 10 µM for integrins α2, α3, α6, β1, β4 and GAPDH are shown in [Table 2](#ijms-19-00587-t002){ref-type="table"}.

4.8. Preparation of Cell Membrane Protein Samples {#sec4dot8-ijms-19-00587}
-------------------------------------------------

IPEC-J2 was grown on glass tissue culture flasks for complete differentiation. Then cell membrane proteins of IPEC-J2 were prepared using a Native Membrane Protein Extraction Kit (Calbiochem, Darmstadt, Germany) according to manufacturer's instructions. The concentration was determined using BCA protein assay kit (Thermo Scientific) and protein samples were stored at −80 °C for the later use.

4.9. SDS-PAGE {#sec4dot9-ijms-19-00587}
-------------

The extracted IPEC-J2 membrane proteins were isolated by SDS-PAGE. Cell membrane proteins were re-suspended in loading buffer (CWBIO, Beijing, China) with the ratio of 4:1 (sample weight to buffer weight). After centrifugation, the supernatant was heated to 95 °C for 3 min. Then the boiled samples were kept in iced condition before loading into the gel. Both 5% stacking gel and 10% separation gel were prepared for separating the proteins. 10 μL of membrane proteins, as well as protein marker (BioLab, Beijing, China) were applied on the gel. The SDS-PAGE was performed at 80 V through the stacking gel and 150 V through the separation gel. After fixation, these proteins were stained with Coomassie brilliant blue at room temperature.

4.10. Co-Immunoprecipitation {#sec4dot10-ijms-19-00587}
----------------------------

Co-Immunoprecipitation experiment was conducted to separate all the specific proteins that specially combined with SBA on IPEC-J2 cell membrane. Co-Immunoprecipitations were carried out using Dynabeads Co-Immunoprecipitation Kit (Invitrogen, Carlsbad, CA, USA). The conditions of all buffers provided in this kit were conducted strictly in accordance with the manufacturer's instructions. Prior to immunoprecipitation, 50 µg of SBA (Sigma) was mixed with beads, and incubated on a roller at 37 °C overnight to make sure the fluid in the tube mix well.

After washing with wash buffer, 1.5 mg prepared SBA-coupled beads were transferred to a fresh tube. Then the SBA-coupled beads were re-suspended in 1.0 g cell membrane samples and incubated on a roller at 4 °C for 30 min. Then the beads were finally re-suspended in EB solution and incubated on a roller at room temperature for 5 min. The immunoprecipitate was centrifuged and the supernatant which contained SBA-binding protein complexes was transferred to a clean tube.

4.11. Liquid Chromatography Coupled to Tandem Mass Spectrometry (LC-MS-MS (Q-E)) Detection {#sec4dot11-ijms-19-00587}
------------------------------------------------------------------------------------------

After separation by co-immunoprecipitation, all SBA associated proteins were detected by Beijing Protein Innovation CO., Ltd. (Beijing, China) and analyzed using an electro-spray ionization tandem mass spectrometry LC-MS-MS (Q-E). MASCOT protein scores (based on combined MS and MS/MS spectra) \> 22 were considered statistically significant (*p* \< 0.05). The individual MS/MS spectrum, with a statistical significant (confidence interval \> 95%) iron score was accepted.

4.12. In Vitro Gene Silencing of ACTN2 {#sec4dot12-ijms-19-00587}
--------------------------------------

For further investigation of the relationship between α-actinin-2 (ACTN2) and integrin subunits, siRNA technique was employed in this study. Cells were seeded in a 6-well plate (5 × 10^4^ per well), after upon reaching 80% confluence, they were used for gene silencing experiment. According to the gene sequences of *ACTN2* specific siRNA in Genbank, we designed three pairs of *ACTN2*-siRNA (Changsha Yingrun Biotechnology, Changsha, China) and their sequences are shown in [Table 4](#ijms-19-00587-t004){ref-type="table"}.

*ACTN2* silencing experiment was divided into five groups: control (untreated cells), negative control (NC), siRNA1 group, siRNA2 group and siRNA3 group. After being diluted in Opti-MEM Medium (Invitrogen), siRNAs and Lipofectamine were mixed and conducted following the manufactural protocol of LipofecAMINE RNAiMAX Reagent (Invitrogen) and cultured at 37 °C for 24 h.

In vitro gene silencing efficacies of the *ACTN2*-siRNA complexes were evaluated by qRT-PCR. The target sequences for *ACTN2* is shown in [Table 2](#ijms-19-00587-t002){ref-type="table"}. Silencing efficacies of different pairs of *ACTN2*-siRNA sequences were compared, and then screened one siRNA sequence with the best silencing efficiency for the next experimental process.

4.13. Determination of the Interaction between SBA, ACTN2 and Integrins from the Gene Levels by qRT-PCR {#sec4dot13-ijms-19-00587}
-------------------------------------------------------------------------------------------------------

Upon reaching 80% confluence, the cells were stimulated with 0 or optimal concentration of SBA for 24 h, total RNA in different SBA treatments were prepared and qRT-PCR was conducted to determine the roles of SBA on mRNA expression of *ACTN2*.

IPEC-J2 was seeded in a 6-well plate (5 × 10^4^ per well) for 80% confluence. Then the cells were treated with 0 or optimal sequences of *ACTN2*-siRNA for 24 h. Their total RNA was extracted and qRT-PCR was used to detect the mRNA levels of integrins in different treatments to explore the relationship between *ACTN2* and gene expression of integrins.

4.14. Statistical Analysis {#sec4dot14-ijms-19-00587}
--------------------------

Each experiment was repeated at least for three times and numerical data were presented as mean ± SEM. Student's *t*-test was used to compare the data between two groups. Data among three or more groups were analyzed with ANOVA followed by the least significant difference (LSD) tests, SPSS Statistics Base 17.0 \[[@B47-ijms-19-00587]\], *p \<* 0.05 was considered significant.

5. Conclusions {#sec5-ijms-19-00587}
==============

Integrins were important for the process of IPEC-J2 apoptosis and SCA. Although there was no direct connection between SBA and integrins, ACTN2 acted as a bridge to connect SBA and integrins. SBA may reduce the mRNA expression of integrins by down regulating the gene expression level of *ACTN2*. These results provided an important evidence and theoretical basic for revealing the anti-nutritional mechanism of SBA, and provided a new way to find the nutritional regulation measures to alleviate the SBA anti-nutritional mechanism. However, whether ACTN2 is the only protein for connecting SBA to integrins is not clear, and still needs to further exploration.
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ACTN2

α-Actinin-2

FCM

Flow cytometry

IPEC-J2

Porcine intestinal columnar epithelial cells

LC-MS-MS

Liquid chromatography coupled to tandem mass spectrometry

MTT

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

NCA

Normal cell apoptosis

qRT-PCR

Quantitative real-time polymerase chain reaction

SBA

Soybean agglutinin

SCA

SBA-induced cell apoptosis

![Effects of SBA on IPEC-J2 proliferation. Cell proliferation was measured by MTT assay at 6 concentrations points (0, 0.125, 0.25, 0.5, 1.0, or 2.0 mg/mL) for 24 h. Absorbance was measured at 570 nm. Means with different superscript are significantly different in compare with its control. Data are represented as mean ± standard error of mean (SEM) (*n* = 3).](ijms-19-00587-g001){#ijms-19-00587-f001}

![(**a**--**f**) Effect of soybean agglutinin (SBA) on the morphology of IPEC-J2 cells (200×). IPEC-J2 was cultured with 0, 0.125, 0.25, 0.5, 1.0 or 2.0 mg/mL SBA for 24 h. Cell morphology was observed in different treatments by contrast microscopy at 200× magnifications. (**a**) Control, 0.000 mg/mL SBA treatment; (**b**) 0.125 mg/mL SBA treatment; (**c**) 0.250 mg/mL SBA treatment; (**d**) 0.500 mg/mL SBA treatment; (**e**) 1.000 mg/mL SBA treatment; (**f**) 2.000 mg/mL SBA treatment.](ijms-19-00587-g002){#ijms-19-00587-f002}

![(**A--F**) SBA induced cell apoptosis in IPEC-J2. IPEC-J2 was cultured with 0, 0.125, 0.25, 0.5, 1.0 or 2.0 mg/mL SBA for 24 h. Cell apoptosis was determined by FCM and shown in Control, 0.000 mg/mL SBA treatment (**A**); 0.125 mg/mL SBA treatment (**B**); 0.250 mg/mL SBA treatment (**C**); 0.500 mg/mL SBA treatment (**D**); 1.000 mg/mL SBA treatment (**E**); 2.000 mg/mL SBA treatment (**F**).](ijms-19-00587-g003){#ijms-19-00587-f003}

![SBA lowered the mRNA expression of Bcl-2 in IPEC-J2. The cells were incubated with 0 or 2.0 mg/mL SBA for 24 h, the effects of SBA on mRNA expression of Bcl-2 were analyzed using qRT-PCR. Means with different superscript are significantly different in compare with its control. Each column is depicted as a mean ± SEM of three independent experiments.](ijms-19-00587-g004){#ijms-19-00587-f004}

![(**a**--**l**) Functions of integrin inhibitors on IPEC-J2 cell apoptosis and SCA. Cell apoptosis in different treatments for 24 h was determined by FCM and shown in (**a**) Control, 0.0 mg/mL SBA treatment; (**b**) 2.0 mg/mL SBA treatment; (**c**) α2 inhibitor treatment; (**d**) α2 inhibitor + 2.0 mg/mL SBA treatment; (**e**) α3 inhibitor treatment; (**f**) α3 inhibitor + 2.0 mg/mL SBA treatment; (**g**) α6 inhibitor treatment; (**h**) α6 inhibitor + 2.0 mg/mL SBA treatment; (**i**) β1 inhibitor treatment; (**j**) β1 inhibitor treatment + 2.0 mg/mL SBA treatment; (**k**) β4 inhibitor treatment; (**l**) β4 inhibitor treatment + 2.0 mg/mL SBA treatment.](ijms-19-00587-g005){#ijms-19-00587-f005}

![Relative mRNA expression of integrin subunits after stimulation by SBA. The mRNA levels of integrins (α2, α3, α6, β1, β4) were measured by qRT-PCR when IPEC-J2s were treated with 0 or 2.0 mg/mL SBA for 24 h. Means with different superscripts are significantly different in compare with its control. Each column is depicted as a mean ± SEM of three independent experiments.](ijms-19-00587-g006){#ijms-19-00587-f006}

![SDS-PAGE of IPEC-J2 membrane proteins. Maker, is a standard that is used to identify the approximate size of a molecule run on a gel during electrophoresis; Lane 1 represents membrane proteins, SDS-PAGE.](ijms-19-00587-g007){#ijms-19-00587-f007}

![(**a**--**d**) The relationship between SBA, integrins and ACTN2. (**a**) Effects of SBA on mRNA expression of *ACTN2* in IPEC-J2. The cells were treated with 0 or 2.0 mg/mL SBA for 24 h, mRNA levels of *ACTN2* were analyzed by qRT-PCR; (**b**) Gene silencing efficiency of siRNA-*ACTN2* in IPEC-J2. After transfection with different pairs Negative control (NC)-siRNA, siRNA1, siRNA2, siRNA3) of siRNA-*ACTN2* sequences for 48 h, mRNA expression levels of *ACTN2* in different siRNA treatments were assessed using qRT-PCR; (**c**) The relative mRNA levels of integrin α2, α3, α6, β1 and β4 in siRNA-*ACTN2* treatment. The cells were treated with control or *ACTN2*-siRNA3 for 24 h and mRNA expression of integrins were detected using qRT-PCR; (**d**) The gene expression trends of different integrins (α2, α3, α6, β1 and β4) in SBA and siRNA-*ACTN2* treatments. Means with different superscripts are significantly different in compare with its control. All values are presented as means ± SEM (*n* = 3).](ijms-19-00587-g008){#ijms-19-00587-f008}
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###### 

Identification of SBA receptors by Q--E analysis.

  No   Name                                       Accession No.   Score   m~w~/PI        Sequence Coverage
  ---- ------------------------------------------ --------------- ------- -------------- -------------------
  1    KRT1                                       F1SGG3          1973    65.381/8.18    14%
  2    KRT14                                      F1S0L1          1309    51.811/4.94    40%
  3    KRT10                                      I3LDS3          1265    58.243/4.93    17%
  4    KRT5                                       F1SGG6          870     63.668/7.74    20%
  5    KRT75                                      F1SGI7          697     65.354/9.27    12%
  6    KRT84                                      F1SGI2          619     54.121/6.12    5%
  7    LOC100737483                               F1SGG9          564     60.375/8.53    19%
  8    MYH13                                      71SS66          550     223.705/5.54   1%
  9    KRT2A                                      A5A759          539     66.510/7.47    8%
  10   KRT3                                       I3LDM6          525     65.497/8.03    11%
  11   PYGM                                       F1RQQ8          507     97.665/6.65    7%
  12   LOC100302368                               F1SRS2          464     26.563/6.85    26%
  13   KRT8                                       F1SGG2          440     54.394/5.70    7%
  14   CKM                                        I3LBJ8          411     43.114/6.91    10%
  15   ALB                                        F1RUN2          409     71.621/5.98    8%
  16   Jup                                        Q8WNW3          399     82.539/5.75    24%
  17   ACTA1                                      P68137          368     42.366/5.23    17%
  18   KRT15                                      F1S0K2          317     49.501/4.87    8%
  19   [l]{.smallcaps}-lactate dehydrogenase      D2SW96          275     36.582/8.18    6%
  20   Myosin-4                                   Q9TV62          245     224.0.1/5.60   2%
  21   LOC100519531                               F1RU49          174     103.873/5.31   5%
  22   SLC25A4                                    F1RZQ6          173     33.233/9.82    14%
  23   GFAP                                       F1RR02          166     49.463/5.32    4%
  24   HUMMLC2B                                   A1XQT5          143     19.066/4.82    10%
  25   CS                                         Q0QEK1          142     24.886/6.59    5%
  26   ACTC1                                      B6VNT8          141     42.334/5.23    18%
  27   MYH4                                       Q9TV62          139     224.010/5.60   1%
  28   DSP                                        F1RW75          129     310.122/6.49   4%
  29   LOC407246                                  I3LL80          108     36.884/5.57    11%
  30   LOC100515788                               F1RII5          107     15.682/7.93    6%
  31   ATP2A2                                     P11607          93      116.371/5.23   3%
  32   PCBP1                                      I3LEC2          93      37.991/6.66    5%
  33   LDHB                                       F1SR05          89      37.108/5.45    5%
  34   GAPDH                                      G3CKJ2          87      29.621/9.29    8%
  35   MB                                         P02189          85      17.074/6.75    10%
  36   Uncharacterized protein                    F1SIX1          84      17.814/5.82    15%
  37   PKM                                        F1SHL9          82      59.256/7.95    2%
  38   HUMMLC2B                                   Q5EEL9          81      10.704/4.80    16%
  39   AK1                                        P00571          75      21.739/8.38    6%
  40   BLVRB                                      I3LQH7          75      22.400/6.35    10%
  41   TMEM38A                                    F1S9V9          74      29.180/8.79    5%
  42   tnnt3                                      Q75NG6          70      29.811/7.74    6%
  43   MYH7                                       F1S9D6          67      223.795/5.59   0%
  44   HUMMLC2B                                   Q5EEL9          59      10.704/4.80    16%
  45   YWHAG                                      F2Z4Z1          55      28.456/4.80    13%
  46   TPI1                                       D0G7F6          51      26.879/6.54    5%
  47   SOD2                                       F1SB60          49      24.923/8.59    9%
  48   Uncharacterized protein                    F1RWF5          49      28.518/5.50    7%
  49   MLC2V                                      A1XQV9          45      16.862/4.57    
  50   ENO2                                       I3LCN1          44      47.438/4.93    5%
  51   LOC100621642                               I3LJ52          39      28.128/6.69    3%
  52   ANXA2                                      P19620          38      38.795/6.49    13%
  53   KRT18                                      A8D349          37      18.038/4.63    10%
  54   PCBP2                                      F1SFQ4          37      37.606/6.60    5%
  55   Beta-actin                                 A0SNU5          37      29.678/5.50    11%
  56   PKP1                                       I3LGN8          36      53.569/9.12    6%
  57   ACTN2                                      F1RHL9          34      104.237/5.31   2%
  58   Glyceraldehyde-3-phosphate dehydrogenase   A0SNU7          34      28.035/6.77    5%
  59   HADH                                       P00348          32      34.197/9/02    11%
  60   PFMK                                       Q1HL06          30      82.443/8.57    2%
  61   ANK2                                       F1S146          28      428.715/4.93   0%
  62   CA3                                        Q5S1S4          28      29.679/7.72    9%
  63   ATP2A1                                     F1RFH9          27      110.403/5.17   3%
  64   METTL3                                     F1S8J8          26      65.501/6.12    1%
  65   CABLES1                                    F1SBB7          26      64.246/9.61    1%
  66   CKMT2                                      Q2HYU1          25      47.961/8.47    3%
  67   VDAC1                                      Q9MZ16          24      30.882/8.62    7%

Accession number in the NCBInr database. m~w~ means molecular weight; PI means isoelectric points. Peptide score is shown as −10log (*p*), where P is the probability that the observed match is a random event. Individual ions scores \>22 indicate identity or extensive homology (*p* \< 0.05). Sequence coverage is shown with the respect to match tryptic digest fragments.
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###### 

Primer sequences of different genes.

  Gene         Accession No.   Forward Primer            Reverse Primer
  ------------ --------------- ------------------------- -------------------------
  Bcl-2        NM_214285.1     TGTGCGTGGAGAGCGTAGA       TAGGTGGTCATTCAGGTAAGTGG
  α2 (ITGA2)   NM_001244272    CGCAGATTACGCTCCTCAAAA     GCTGAACAACAGTCCCACTCC
  α3 (ITGA3)   XM_005668879    AGCGTCCCCACCATCAA         CTCACAGCCACAAGCACCA
  α6 (ITGA6)   XM_005657544    TGTGACTGTGTTTCCCTCAAAGA   AGCATCAAAATCCCAGCAAGA
  β1 (ITGB1)   XM_003131195    TGAGTGCAACCCCAACTACAC     CAGACCCCACATTCACAGACA
  β4 (ITGB4)   NM_213968.1     CAGGGCTACAGCGTGGAGTA      TAGGAGTGGTTGGGCAGAAGA
  *ACTN2*      NM_001243666    GGCATACGGCAAAGAGCA        GGCGTCGTGATAGTCCAGTT
  GAPDH        NM_001206359    TGCACCACCAACTGCTTGGC      GGCATGGACCGTGGTCATGAG
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###### 

Divided groups in integrin inhibitor experiment.

  Treatment Number   SBA Level   Integrin Inhibitor Type
  ------------------ ----------- -------------------------
  1 (control)        \-          \-
  2                  SBA         \-
  3                  \-          α2 inhibitor
  4                  SBA         α2 inhibitor
  5                  \-          α3 inhibitor
  6                  SBA         α3 inhibitor
  7                  \-          α6 inhibitor
  8                  SBA         α6 inhibitor
  9                  \-          β1 inhibitor
  10                 SBA         β1 inhibitor
  11                 \-          β4 inhibitor
  12                 SBA         β4 inhibitor
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###### 

Target siRNA sequences of *ACTN2*.

  Gene Name        Forward Primer          Reverse Primer
  ---------------- ----------------------- -----------------------
  *ACTN2*-siRNA1   GCACUCAGAUCGAGAACAUTT   AUGUUCUCGAUCUGAGUGCTT
  *ACTN2*-siRNA2   GCAUGAUCUGGACCAUUAUTT   AUAAUGGUCCAGAUCAUGCTT
  *ACTN2*-siRNA3   GGUUCUUGCUGUGAAUCAATT   UUGAUUCACAGCAAGAACCTT
  NC-siRNA         GACTTCATAAGGCGCATGC     GCATGCGCCTTATGAAGTC
